Patents by Inventor Paul Polakis

Paul Polakis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9994643
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: June 12, 2018
    Assignee: Genentech, Inc.
    Inventors: Mark Dennis, Bonnee Rubinfeld, Paul Polakis
  • Publication number: 20180134717
    Abstract: Conjugates and compounds for making conjugates which are PBD molecules linked via the N10 position are disclosed, along with the use of the conjugates for treating proliferative diseases, including cancer.
    Type: Application
    Filed: October 4, 2017
    Publication date: May 17, 2018
    Inventors: Philip Wilson HOWARD, Luke Masterson, Arnaud Tiberghien, John A. Flygare, Janet L. Gunzner, Paul Polakis, Andrew Polson, Helga E. Raab, Susan D. Spencer
  • Publication number: 20180106809
    Abstract: Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided.
    Type: Application
    Filed: December 21, 2017
    Publication date: April 19, 2018
    Applicant: Genentech, Inc.
    Inventors: Mark S. Dennis, Bonnee Rubinfeld, Paul Polakis, Aya Jakobovits
  • Patent number: 9926377
    Abstract: The invention provides anti-GPC3 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: March 27, 2018
    Assignee: Genentech, Inc.
    Inventors: Paul Polakis, Youjun Chen
  • Publication number: 20180015179
    Abstract: The invention provides anti-CD79b antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: June 26, 2017
    Publication date: January 18, 2018
    Applicant: Genentech, Inc.
    Inventors: Paul Polakis, Andrew G. Polson, Susan Diane Spencer, Shang-Fan Yu, Bing Zheng
  • Publication number: 20170349639
    Abstract: The present invention provides for chimeric Wnt antagonists comprising a Frz domain component derived from a Frizzled protein, a secreted Frizzled related protein or Ror protein and an Fc immunoglobulin component, and their use in the treatment and diagnostic detection of cellular Wnt signaling and Wnt-mediated disorders, including cancer.
    Type: Application
    Filed: December 20, 2016
    Publication date: December 7, 2017
    Applicant: Genentech, Inc.
    Inventors: James A. ERNST, Paul POLAKIS, Bonnee RUBINFELD, Venita I. DEALMEIDA
  • Publication number: 20170326248
    Abstract: The invention provides anti-CD22 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: April 26, 2017
    Publication date: November 16, 2017
    Applicant: GENENTECH, INC
    Inventors: Paul Polakis, Andrew G. Polson, Susan Diane Spencer, Shang-Fan Yu, Bing Zheng
  • Patent number: 9815905
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: November 14, 2017
    Assignee: Genentech, Inc.
    Inventors: Paul Polakis, Jyoti Asundi, Ron Firestein, Robert F. Kelley, Krista McCutcheon
  • Publication number: 20170290920
    Abstract: The invention provides anti-CD22 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: April 26, 2017
    Publication date: October 12, 2017
    Applicants: MEDIMMUNE LIMITED, GENENTECH, INC.
    Inventors: Paul Polakis, Andrew Polson, Susan Diane Spencer, Shang-Fan Yu, John A. Flygare, Janet L. Gunzner-Toste, Thomas H. Pillow, Philip Wilson Howard, Luke Masterson
  • Publication number: 20170239366
    Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: December 21, 2016
    Publication date: August 24, 2017
    Applicant: Genentech, Inc.
    Inventors: Steven R. LEONG, Andrew POLSON, Paul POLAKIS, Yan WU, Wei-Ching LIANG, Ron FIRESTEIN
  • Publication number: 20170240645
    Abstract: The invention provides anti-PMEL17 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: February 6, 2017
    Publication date: August 24, 2017
    Applicant: GENENTECH, INC.
    Inventors: Youjun Chen, William Mallet, Paul Polakis, Christine Tan, Jyoti Asundi, Suzanna Clark
  • Publication number: 20170234883
    Abstract: Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided.
    Type: Application
    Filed: January 25, 2017
    Publication date: August 17, 2017
    Applicant: Genentech, Inc.
    Inventors: Mark S. DENNIS, Bonnee RUBINFELD, Paul POLAKIS, Aya JAKOBOVITS
  • Patent number: 9695240
    Abstract: The present invention relates to conjugates of therapeutically useful anthracyclines with carriers such as polyclonal and monoclonal antibodies, proteins or peptides of natural or synthetic origin; methods for their preparation, pharmaceutical composition containing them and use thereof in treating certain mammalian tumors.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: July 4, 2017
    Assignees: Genentech, Inc., Nerviano Medical Sciences S.R.L.
    Inventors: Italo Beria, Michele Caruso, John A. Flygare, Vittoria Lupi, Rita Perego, Paul Polakis, Andrew Polson, Matteo Salsa, Susan D. Spencer, Barbara Valsasina, Robert L. Cohen
  • Publication number: 20170166635
    Abstract: Cysteine engineered anti-TENB2 antibodies are engineered by replacing one or more amino acids of a parent anti-TENB2 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-TENB2 antibodies are provided. Cysteine engineered anti-TENB2 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-TENB2 antibody-drug conjugates having Formula I: Ab-(L-D)p ??(I) where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
    Type: Application
    Filed: November 8, 2016
    Publication date: June 15, 2017
    Inventors: Weiguang Mao, Jagath Reddy Junutula, Paul Polakis
  • Publication number: 20170121424
    Abstract: Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of detecting or determining the presence of STEAP-1 proteins are provided.
    Type: Application
    Filed: October 10, 2016
    Publication date: May 4, 2017
    Applicant: Genentech, Inc.
    Inventors: Mark DENNIS, Jan MARIK, Paul POLAKIS, Bonnee RUBINFELD, Simon WILLIAMS
  • Patent number: 9597411
    Abstract: The invention provides anti-PMEL17 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: March 21, 2017
    Assignee: Genentech, Inc.
    Inventors: Youjun Chen, William Mallet, Paul Polakis, Christine Tan, Jyoti Asundi, Suzanna Clark
  • Publication number: 20170073424
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: November 2, 2016
    Publication date: March 16, 2017
    Applicant: Genentech, Inc.
    Inventors: Mark Dennis, Bonnee Rubinfeld, Paul Polakis
  • Patent number: 9593167
    Abstract: Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: March 14, 2017
    Assignee: GENENTECH, INC.
    Inventors: Mark S. Dennis, Bonnee Rubinfeld, Paul Polakis, Aya Jakobovits
  • Publication number: 20170058042
    Abstract: The invention provides anti-Ly6E antibodies, immunoconjugates and methods of using the same.
    Type: Application
    Filed: February 8, 2016
    Publication date: March 2, 2017
    Inventors: Jyoti Asundi, Ron Firestein, Paul Polakis, Chie Sakanaka, Peter Chang, Rayna Takaki Venook
  • Patent number: 9562099
    Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: February 7, 2017
    Assignee: Genentech, Inc.
    Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein